Strides Pharma Science Ltd. (earlier known as Strides Pharma Inc.) plans to invest up to $40m for a controlling stake in Indian firm Stelis Biopharma Pvt. Ltd. in a strategic move to gain re-entry into the injectable generics business and capitalize on the latter’s imminent growth prospects.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?